Search details
1.
A Phase II Open-Label Trial of Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS-Mutant Non-Small Cell Lung Cancer.
Oncologist
; 28(7): 644-e564, 2023 07 05.
Article
in English
| MEDLINE | ID: mdl-37186063
2.
Very high PD-L1 expression as a prognostic indicator of overall survival among patients with advanced non-small cell lung cancer receiving anti-PD-(L)1 monotherapies in routine practice.
Pharmacoepidemiol Drug Saf
; 31(10): 1121-1126, 2022 10.
Article
in English
| MEDLINE | ID: mdl-35670103
3.
Impact of telemedicine adoption on accessibility and time to treatment in patients with thoracic malignancies during the COVID-19 pandemic.
BMC Cancer
; 21(1): 1094, 2021 Oct 11.
Article
in English
| MEDLINE | ID: mdl-34635061
4.
Combination Immunotherapy in Non-small Cell Lung Cancer.
Curr Oncol Rep
; 20(7): 55, 2018 05 08.
Article
in English
| MEDLINE | ID: mdl-29740718
5.
Patterns of Failure, Low-Volume Relapse, and Subsequent Ablative Management in Locally Advanced Non-Small Cell Lung Cancer Treated With Definitive Chemoradiation and Consolidation Immune Checkpoint Inhibitors.
Int J Radiat Oncol Biol Phys
; 118(5): 1435-1444, 2024 Apr 01.
Article
in English
| MEDLINE | ID: mdl-37866762
6.
Patterns of Failure in Metastatic NSCLC Treated With First Line Pembrolizumab and Use of Local Therapy in Patients With Oligoprogression.
Clin Lung Cancer
; 25(1): 50-60.e6, 2024 01.
Article
in English
| MEDLINE | ID: mdl-37813713
7.
Phase 2 Trial of Consolidation Pembrolizumab After Proton Reirradiation for Thoracic Recurrences of Non-Small Cell Lung Cancer.
Int J Radiat Oncol Biol Phys
; 119(1): 56-65, 2024 May 01.
Article
in English
| MEDLINE | ID: mdl-37652303
8.
Plunging Into the PACIFIC: Outcomes of Patients With Unresectable KRAS-Mutated Non-Small Cell Lung Cancer Following Definitive Chemoradiation and Durvalumab Consolidation.
Clin Lung Cancer
; 25(3): e161-e171, 2024 May.
Article
in English
| MEDLINE | ID: mdl-38195320
9.
The Efficacy and Safety of Treating Acquired MET Resistance Through Combinations of Parent and MET Tyrosine Kinase Inhibitors in Patients With Metastatic Oncogene-Driven NSCLC.
JTO Clin Res Rep
; 5(2): 100637, 2024 Feb.
Article
in English
| MEDLINE | ID: mdl-38361741
10.
Chemoimmunotherapy vs. Immunotherapy for First Line Treatment of Advanced Non-small Cell Lung Cancer With a PD-L1 Expression ≥50% or ≥90.
Clin Lung Cancer
; 24(3): 235-243, 2023 05.
Article
in English
| MEDLINE | ID: mdl-36935244
11.
Association Between Duration of Immunotherapy and Overall Survival in Advanced Non-Small Cell Lung Cancer.
JAMA Oncol
; 9(8): 1075-1082, 2023 08 01.
Article
in English
| MEDLINE | ID: mdl-37270700
12.
Brief Report: Second-line treatment outcomes in patients with advanced NSCLC previously treated with first-line immunotherapy regimens.
Clin Lung Cancer
; 24(6): 558-562.e2, 2023 09.
Article
in English
| MEDLINE | ID: mdl-37451933
13.
A Multicenter Retrospective Chart Review of Clinical Outcomes Among Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer.
Clin Lung Cancer
; 24(3): 228-234, 2023 05.
Article
in English
| MEDLINE | ID: mdl-36841727
14.
Utilization and Factors Precluding Receipt of Checkpoint Inhibitor Consolidation for Stage III NSCLC in a Large US Academic Health System.
Clin Lung Cancer
; 24(5): 474-482, 2023 07.
Article
in English
| MEDLINE | ID: mdl-37076396
15.
Clinical Outcomes Associated With Pembrolizumab Monotherapy Among Adults With Diffuse Malignant Peritoneal Mesothelioma.
JAMA Netw Open
; 6(3): e232526, 2023 03 01.
Article
in English
| MEDLINE | ID: mdl-36897589
16.
Association Between Availability of Molecular Genotyping Results and Overall Survival in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer.
JCO Precis Oncol
; 7: e2300191, 2023 07.
Article
in English
| MEDLINE | ID: mdl-37499192
17.
Disparities in outcomes between Black and White patients in North America with thoracic malignancies and COVID-19 infection (TERAVOLT).
Lung Cancer
; 186: 107423, 2023 12.
Article
in English
| MEDLINE | ID: mdl-37995456
18.
Association Between Survival and Very High Versus High PD-L1 Expression in Patients Receiving Pembrolizumab as First-line Treatment for Advanced Non-Small Cell Lung Cancer.
Clin Lung Cancer
; 23(8): 731-736, 2022 12.
Article
in English
| MEDLINE | ID: mdl-35945127
19.
Platinum Re-Exposure as a Non-Small Cell Lung Cancer (NSCLC) Treatment Strategy in the Age of Immunotherapy.
Clin Lung Cancer
; 23(4): e301-e309, 2022 06.
Article
in English
| MEDLINE | ID: mdl-35093294
20.
Phase II Trial of Combination Nab-paclitaxel and Gemcitabine in Non-squamous Non-small Cell Lung Cancer After Progression on Platinum and Pemetrexed.
Clin Lung Cancer
; 23(4): e310-e316, 2022 06.
Article
in English
| MEDLINE | ID: mdl-35393247